Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Conduit Pharmaceuticals Inc. (CDT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: CDT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -33.52% | Avg. Invested days 63 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.74M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2 | 52 Weeks Range 2.21 - 1560.00 | Updated Date 06/29/2025 |
52 Weeks Range 2.21 - 1560.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -255.6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -168.26% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3484180 | Price to Sales(TTM) - |
Enterprise Value 3484180 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -55.41 | Shares Outstanding 952229 | Shares Floating 552357 |
Shares Outstanding 952229 | Shares Floating 552357 | ||
Percent Insiders 18.39 | Percent Institutions 3.63 |
Upturn AI SWOT
Conduit Pharmaceuticals Inc.
Company Overview
History and Background
Conduit Pharmaceuticals Inc., founded in 2020, focuses on developing and commercializing innovative treatments targeting unmet medical needs. It aims to in-license and develop promising therapies from academic institutions and other pharmaceutical companies.
Core Business Areas
- In-licensing and Development: Acquiring rights to promising drug candidates and advancing them through preclinical and clinical development.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of drug candidates.
- Commercialization: Preparing for the commercial launch and marketing of approved therapies.
Leadership and Structure
Dr. Fredrik Wiklund serves as the Chief Executive Officer. The company's structure consists of research and development, clinical operations, and commercialization teams.
Top Products and Market Share
Key Offerings
- AZD1656: A fructose-1,6-bisphosphatase (FBPase) inhibitor licensed from AstraZeneca. The company plans to initiate a Phase 2 clinical trial in patients with diabetes in H1 2024. Competitors include other diabetes treatments from companies such as Novo Nordisk (NVO) and Eli Lilly (LLY).
- Remogliflozin etabonate: A selective inhibitor of the sodium glucose co-transporter 2 (SGLT2). The company plans to initiate a Phase 2 clinical trial in patients with diabetes and heart failure in H1 2024. Competitors include other SGLT2 inhibitors from companies such as Johnson & Johnson (JNJ) and Boehringer Ingelheim.
Market Dynamics
Industry Overview
The pharmaceutical industry is experiencing growth driven by increasing healthcare spending, aging populations, and advancements in drug development technologies.
Positioning
Conduit Pharmaceuticals is positioned as a company focused on in-licensing and developing promising drug candidates to address unmet medical needs, aiming for niche markets where current treatments are inadequate.
Total Addressable Market (TAM)
The TAM for diabetes and heart failure treatments is estimated to be billions of dollars. Conduit Pharmaceuticals is positioned to capture a share of this market by offering differentiated therapies.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Focus on in-licensing de-risked assets
- Strong pipeline of drug candidates
Weaknesses
- Dependence on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- High regulatory hurdles and development risks
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Accelerated approval pathways for innovative therapies
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
- Johnson & Johnson (JNJ)
Competitive Landscape
Conduit Pharmaceuticals faces significant competition from established pharmaceutical companies with larger resources and broader product portfolios. Its competitive advantage lies in its focus on in-licensing de-risked assets and developing innovative therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's recent establishment. Growth is anticipated upon successful clinical trial completion and product commercialization.
Future Projections: Future growth projections depend on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary depending on the success of the pipeline.
Recent Initiatives: Initiating Phase 2 clinical trials for AZD1656 and Remogliflozin etabonate are key recent initiatives.
Summary
Conduit Pharmaceuticals is a young company with potential in developing niche therapies. Its success hinges on successful clinical trials. Competition from established firms poses a significant challenge, and managing its financial resources will be crucial for future growth. The company's in-licensing strategy provides a promising avenue for expanding its portfolio.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- Analyst Reports
- SEC Filings
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on individual circumstances and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Conduit Pharmaceuticals Inc.
Exchange NASDAQ | Headquaters Naples, FL, United States | ||
IPO Launch date 2023-09-25 | Founder, CEO & Director Dr. Andrew Regan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.conduitpharma.com |
Full time employees 6 | Website https://www.conduitpharma.com | ||
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in Naples, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.